CMR Naviscan Corporation

CMR Naviscan Corporation manufactures and markets molecular breast imaging (MBI) systems for breast cancer detection and diagnosis. The company's primary product is the lumaGEM system, a gamma imaging platform designed for screening and diagnostic applications in breast imaging. The lumaGEM system is used as a primary screening option, secondary screening modality for high-risk patients and those with dense breast tissue, and for adjunct evaluation of occult primary breast carcinoma and equivocal conventional imaging findings. The company also offers the Solo II imaging platform and Stereo Navigator navigation system. Clinical data presented on their site demonstrates increased invasive cancer detection rates, reduction of benign biopsies in women with dense breast tissue compared to other modalities, and lower cost per cancer detected when MBI is added to screening mammography. The lumaGEM system is positioned to address the significant clinical challenge of dense breast tissue, where both cancer and fibroglandular tissue appear white on conventional mammography, reducing sensitivity. CMR Naviscan's solutions are used by radiologists and breast cancer centers for both screening and diagnostic purposes, with published evidence supporting efficacy in early cancer detection. The company participates in major industry conferences such as the Society of Breast Imaging symposium.